Achilles Therapeutics Recognized with the 2022 PING Innovation Award
21. Juni 2022 08:30 ET
|
Achilles Therapeutics PLC
LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
10. Mai 2022 07:00 ET
|
Achilles Therapeutics PLC
- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma - ...
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
09. Mai 2022 07:00 ET
|
Achilles Therapeutics PLC
- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from...
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
04. Mai 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Present at Upcoming Conferences
03. Mai 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
12. April 2022 07:30 ET
|
Achilles Therapeutics PLC
– Expansion will supply clinical grade cNeT for ongoing Phase I/IIa clinical trials and support future development – LONDON, April 12, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:...
Achilles Therapeutics to Present at Upcoming Conferences
05. April 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
04. April 2022 08:00 ET
|
Achilles Therapeutics PLC
- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS...
Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
08. März 2022 08:00 ET
|
Achilles Therapeutics PLC
LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights
01. März 2022 07:02 ET
|
Achilles Therapeutics PLC
- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and...